GLP-1 Pharmacovigilance
Sex-stratified pharmacovigilance signal detection for GLP-1 receptor agonists using 18.5M+ harmonized FDA Adverse Event Reporting System records. Applies disproportionality analysis methods to identify hypothesis-generating signals across demographic and temporal dimensions. Results are exploratory and do not support causal inference.
Methods
Technologies